PMID- 1329168
OWN - NLM
STAT- MEDLINE
DCOM- 19921123
LR  - 20191028
IS  - 0923-2516 (Print)
IS  - 0923-2516 (Linking)
VI  - 143
IP  - 4
DP  - 1992 Jul-Aug
TI  - Mucosal delivery of herpes simplex virus vaccine.
PG  - 269-78
AB  - The mucosal route for the production of mucosal and systemic herpes simplex virus 
      (HSV) antibodies was investigated using HSV1 subunit vaccine administered to 
      guinea pigs. Groups of test animals (n = 13) were dosed, nasally or vaginally and 
      compared with those injected subcutaneously (s.c.). The vaccines, in aqueous or 
      gel form, were administered 5 and 3 weeks prior to vaginal challenge with HSV2 
      suspension. Control infected and non-infected animals were included for 
      comparison. Animals which were vaccinated s.c. were shown to respond to 
      subsequent infection with HSV by the production of serum HSV-specific IgG (and 
      IgA) but negligible amounts of vaginal IgG and IgA. Control non-infected and 
      infected-only groups produced none and only a small amount of vaginal 
      HSV-specific antibodies, respectively. Substantial protection against HSV2 
      infection of the female guinea pig genital tract was provided by s.c. 
      immunization with HSV vaccine. Protection was evaluated in terms of the reduction 
      of histopathological lesions and clinical signs in vaccinated and control 
      animals. The serum humoral response to nasal delivery in phosphate-buffered 
      saline was comparable, and was superior for vaginal washes to that of parenteral 
      vaccination. The nasally delivered free antigen gave significant (p < or = 0.05) 
      reduction in the severity of the disease and higher levels of specific serum and 
      vaginal immunoglobulin antibodies to HSV when compared with non-immunized 
      infected-only controls, probably due to uptake of antigenically intact protein. 
      Vaginal gel treatment slightly reduced the severity of the illness and gave 
      higher humoral responses than those induced by vaginally delivered free antigen. 
      Findings also indicate that these mucosal immune responses were produced at a 
      site distant from the site of vaccination, suggesting a common immunological 
      system.
FAU - Bowen, J C
AU  - Bowen JC
AD  - Department of Pharmaceutical Sciences, Aston University, Birmingham, UK.
FAU - Alpar, H O
AU  - Alpar HO
FAU - Phillpotts, R
AU  - Phillpotts R
FAU - Brown, M R
AU  - Brown MR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Res Virol
JT  - Research in virology
JID - 8907469
RN  - 0 (Antibodies, Viral)
RN  - 0 (Dosage Forms)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Administration, Intranasal
MH  - Administration, Intravaginal
MH  - Animals
MH  - Antibodies, Viral/*blood
MH  - Dosage Forms
MH  - Female
MH  - Guinea Pigs
MH  - Herpes Simplex/*prevention & control
MH  - Immunoglobulin A/*blood
MH  - Immunoglobulin G/*blood
MH  - Injections, Subcutaneous
MH  - Simplexvirus/*immunology
MH  - Viral Vaccines/*administration & dosage
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - 10.1016/s0923-2516(06)80115-9 [doi]
PST - ppublish
SO  - Res Virol. 1992 Jul-Aug;143(4):269-78. doi: 10.1016/s0923-2516(06)80115-9.